


Treat the source of pain without a pill




Did you know that 40% of Canadians say that taking even one pill less a day would make them feel less overwhelmed?¹

Voltaren Emulgel – Fight inflammation at the source of pain without taking a pill²


Voltaren Emulgel[†] enhances the penetration of diclofenac^{††} through the skin³



Formulated for absorption of diclofenac through the skin³



Sustained release of diclofenac into underlying tissues²



Penetrates deeply to reduce pain and inflammation at the source⁴

[†] Refers to Voltaren Emulgel Extra Strength 2.32% gel


^{††} Diclofenac is a non-steroidal anti-inflammatory drug (NSAID) analgesic agent for topical use.²

Voltaren Emulgel 1.16% and Voltaren Emulgel Back & Muscle Pain (diclofenac diethylamine gel) are indicated for relief of pain associated with recent (acute), localized muscle or joint injuries such as sprains, strains or sports injuries (e.g. ankle sprain, shoulder strain or back muscle pain). This is typically as an adjunct to other measures, such as rest, for the relief of discomfort associated with such injuries.

Voltaren Emulgel Extra Strength 2.32% and Voltaren Emulgel Joint Pain Extra Strength 2.32% (diclofenac diethylamine gel) are indicated for relief of pain associated with recent (acute), localized, minor muscle or joint injuries such as sprains, strains or sports injuries (e.g. ankle sprain, shoulder strain or back muscle pain). This is typically as an adjunct to other measures, such as rest, for the relief of discomfort associated with such injuries.

Voltaren Emulgel decreases inflammation to treat the root cause of pain²

In clinical studies, Voltaren Emulgel has demonstrated:




inhibition of inflammation in the first 4 hours after 1 application⁵



inhibition of inflammation even 48 hours after 1 application^{2,5}

In clinical studies, Voltaren Emulgel has demonstrated:



1. Edelman Berland - Novartis. Global Pain Index. February 4, 2015. 2. GlaxoSmithKline Consumer Healthcare. Voltaren Emulgel Product Monograph. June 2, 2017. 3. Ajazuddin, Alexander, A., Khichariya, A., et al. Recent expansions in an emergent novel drug delivery technology: *Emulgel*. *J Control Release*. 2013. 171:122-32. 4. Singh, P. and Roberts, M. S. Skin permeability and local tissue concentrations of nonsteroidal anti-inflammatory drugs after topical application. *J Pharmacol Exp Ther*. 1994. 268:144-51. 5. Duteil, L., Queille, C., Poncet, M., et al. Objective assessment of topical corticosteroids and non-steroidal anti-inflammatory drugs in methyl-nicotinate-induced skin inflammation. *Clin Exp Dermatol*. 1990. 15:195-9.